1
|
Weng CJ, Chau CF, Hsieh YS, Yang SF and
Yen GC: Lucidenic acid inhibits PMA-induced invasion of human
hepatoma cells through inactivating MAPK/ERK signal transduction
pathway and reducing binding activities of NF-κB and AP-1.
Carcinogenesis. 29:147–156. 2008.PubMed/NCBI
|
2
|
Kato Y, Yamashita T and Ishikawa M:
Relationship between expression of matrix metalloproteinase-2 and
matrix metalloproteinase-9 and invasion ability of cervical cancer
cells. Oncol Rep. 9:565–569. 2002.PubMed/NCBI
|
3
|
Liotta LA, Steeg PS and Stetler-Stevenson
WG: Cancer metastasis and angiogenesis: an imbalance of positive
and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
|
4
|
Rao JS: Moleculae mechanisms of glioma
invasiveness: the role of proteases. Nat Rev Cancer. 3:489–501.
2003. View
Article : Google Scholar : PubMed/NCBI
|
5
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
6
|
Nabeshima K, Inoue T, Shimao Y and
Sameshima T: Matrix metalloproteinases in tumor invasion: Role for
cell migration. Pathol Int. 52:255–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yan C and Boyd DD: Regulation of matrix
metalloproteinase gene expression. J Cell Physiol. 211:19–26. 2007.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Cho HJ, Kang JH, Kwak JY, Lee TS, Lee IS,
Park NG, Nakajima H, Magae J and Chang YC: Ascofuranone suppresses
PMA-mediated matrix metalloproteinase-9 gene activation through the
Ras/Raf/MEK/ERK-and Ap1-dependent mechanisms. Carcinogenesis.
28:1104–1110. 2007. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sato H and Seiki M: Regulatory mechanism
of 92 kDa type IV collagenase gene expression which is associated
with invasiveness of tumor cells. Oncogene. 8:395–405.
1993.PubMed/NCBI
|
10
|
Sato H, Kita M and Seiki M: v-Src
activates the expression of 92-kDa type IV collagenase gene through
the AP-1 site and the GT box homologous to retinoblastoma control
elements. A mechanism regulating gene expression independent of
that by inflammatory cytokines. J Biol Chem. 268:23460–23468.
1993.
|
11
|
Takahra T, Smart DE, Oakley F and Mann DA:
Induction of myofibroblast MMP-9 transcription in three-dimensional
collagen I gel cultures: regulation by NF-κB, AP-1 and Sp1. Int J
Biochem Cell Biol. 36:353–363. 2004.PubMed/NCBI
|
12
|
Attele AS, Wu JA and Yuan CS: Ginseng
pharmacology: multiple constituents and multiple actions. Biochem
Pharmacol. 58:1685–1693. 1999. View Article : Google Scholar : PubMed/NCBI
|
13
|
Xu L, Chen WF and Wong MS: Ginsenoside Rg1
protects dopaminergic neurons in a rat model of Parkinson’s disease
through the IGF-I receptor signalling pathway. Br J Pharmacol.
158:738–748. 2009.PubMed/NCBI
|
14
|
Liu Q, Kou JP and Yu BY: Ginsenoside Rg1
protects against hydrogen peroxide-induced cell death in PC12 cells
via inhibiting NF-κB activation. Neurochem Int. 58:119–125.
2011.PubMed/NCBI
|
15
|
Li CY, Deng W, Liao XQ, Deng J, Zhang YK
and Wang DX: The effects and mechanism of ginsenoside Rg1 on
myocardial remodeling in an animal model of chronic thromboembolic
pulmonary hypertension. Eur J Med Res. 18:162013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yin H, Liu Z, Li F, Ni M, Wang B, Qiao Y,
Xu X, Zhang M, Zhang J, Lu H and Zhang Y: Retraction note to:
Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular
remodeling in a rat model of myocardial infarction. J Mol Med.
91:6452013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Lee EJ, Ko E, Lee J, Rho S, Ko S, Shin MK,
Min BI, Hong MC, Kim SY and Bae H: Ginsenoside Rg1 enhances
CD4+ T-cell activities and modulates Th1/Th2
differentiation. Int Immunopharmacol. 4:235–244. 2004. View Article : Google Scholar
|
18
|
Qu DF, Yu HJ, Liu Z, Zhang DF, Zhou QJ,
Zhang HL and Du AF: Ginsenoside Rg1 enhances immune response
induced by recombinant Toxoplasma gondii SAG1 antigen. Vet
Parasitol. 179:28–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Li QF, Shi SL, Liu QR, Tang J, Song J and
Liang Y: Anticancer effects of ginsenoside Rg1, cinnamic acid, and
tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix
downregulation and cytoplasmic trafficking of nucleophosmin. Int J
Biochem Cell Biol. 40:1918–1929. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Liu J, Cai SZ, Zhou Y, Zhang XP, Liu DF,
Jiang R and Wang YP: Senescence as a consequence of ginsenoside rg1
response on k562 human leukemia cell line. Asian Pac J Cancer Prev.
13:6191–6196. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al
Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-talk
between NFκB and the PI3-kinase/AKT pathway can be targeted in
primary effusion lymphoma (PEL) cell lines for efficient apoptosis.
PLos One. 7:e399452012.
|
22
|
Hussain AR, Ahmed M, Al-Jomah NA, Khan AS,
Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS and
Uddin S: Curcumin suppresses constitutive activation of nuclear
factor-κB and requires functional Bax to induce apoptosis in
Burkitt’s lymphoma cell lines. Mol Cancer Ther. 7:3318–3329.
2008.PubMed/NCBI
|
23
|
Kim KS, Yao L, Lee YC, Chung E, Kim KM,
Kwak YJ, Kim SJ, Cui Z and Lee JH: Hyul-Tong-Ryung suppresses
PMA-induced MMP-9 expression by inhibiting AP-1-mediated gene
expression via ERK1/2 signaling pathway in MCF-7 human breast
cancer cells. Immunopharmacol Immunotoxicol. 32:600–606. 2010.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Yao L, Kim KS and Kang NY: Inhibitory
effect of a traditional Chinese formulation, Hyul-Tong-Ryung, on
PMA-induced MMP-9 expression in MCF-7 human breast carcinoma cells.
J Trad Med. 26:25–34. 2009.
|
25
|
Han SY, Lee MS, Kim HR, Baek SH, Ahn DH,
Chae HS, Erickson RH, Sleisenger MH and Kim YS: Phorbol
12-myristate 13-acetate induces alteration in mucin gene expression
and biological properties of colon cancer cells. Int J Oncol.
17:487–494. 2000.PubMed/NCBI
|
26
|
Lin CW, Shen SC, Hou WC, Yang L and Chen
YC: Heme oxygenase-1 inhibits breast cancer invasion via
suppressing the expression of matrix metalloproteinase-9. Mol
Cancer Ther. 7:1195–1206. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Scorilas A, Karameris A, Arnogiannaki N,
Ardavanis A, Bassilopoulos P, Trangas T and Talieri M:
Overexpression of matrix-metalloproteinase-9 in human breast
cancer: a potential favourable indicator in node-negative patients.
Br J Cancer. 84:1488–1496. 2001. View Article : Google Scholar
|